AbbVie
Biogen gets go-ahead for EU Humira launch in October
AbbVie, Biogen, inflammatory diseases, litigation, patent, Samsung Bioepis
0 Comment
But deal with Samsung prevents US launch until mid-2023
AbbVie to file long-acting psoriasis contender
AbbVie, inflammatory diseases, Johnson & Johnson, psoriasis
0 Comment
AbbVie hopes risankizumab will rebuild sales after Humira patent expires
AbbVie signs $225m ‘immunoneurology’ deal to tackle Alzheimer’s
AbbVie, Alector, Alzheimer's disease, immuno-neurology
0 Comment
Partnership will use novel approach to treating Alzheimer’s.
Ready to pounce: Samsung joins Amgen with Humira biosimilar approval
Amgen, biosimilars, inflammatory diseases, Rheumatoid arthritis, Samsung Bioepis
0 Comment
No-one can launch biosimilars until patent expires next year
Janssen/AbbVie drug approved in graft-versus-host disease
AbbVie, cancer, graft versus host disease, Johnson & Johnson
0 Comment
First use for Imbruvica outside blood cancer.
AbbVie, Gilead target sick hepatitis C patients in EU
hepatitis C, infectious diseases, market access, regulation
0 Comment
UK court overturns AbbVie Humira patents
AbbVie, Amgen, litigation, patent, psoriasis, Rheumatoid arthritis, Samsung Bioepis
0 Comment
Decision paves way for cheaper competitor in autumn 2018.
NICE rejects AbbVie/Roche CLL drug Venclyxto
blood cancer, cancer, chronic lymphocytic leukaemia, cost-effectiveness, NICE, pricing
0 Comment
Body unconvinced by clinical data for Venclyxto .